For the treatment and prevention of osteoporosis in postmenopausal women.
Boniva Mechanism Of Action:
The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Boniva Drug Interactions:
Aluminium Formation of non absorbable complexes
Bismuth Formation of non absorbable complexes
Calcium Formation of non absorbable complexes
Iron Formation of non absorbable complexes
Magnesium oxide Formation of non absorbable complexes
Magnesium Formation of non absorbable complexes
Sucralfate Formation of non absorbable complexes
Boniva Food Interactions:
Take on an empty stomach. All foods markedly reduce (up to 90%) ibandronate bioavailabilty. Take with plain water (not mineralized) 1 hour before any food. Bioavailability and effect on bone density are both impaired if the patient eats or drinks less than 1 hour after taking this product. Drink a large glass of water and stay in an upright position for at least 60 minutes after taking this product.
LD50 = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.